Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus reuteri plus triple therapy for Helicobacter pylori eradication
IRCT20201225049825N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jan 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of lactobacillus reuteri in Helicobacter pylori infection, sponsored by Arak University of Medical Sciences. Started Jan 2021; status: completed.
02
Drugs
lactobacillus reuteri
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20201225049825N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201225049825N1.